992 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by denkapparat Operations GmbH

denkapparat Operations GmbH bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 992 shares of the pharmaceutical company's stock, valued at approximately $399,000.

Other large investors also recently made changes to their positions in the company. Norges Bank purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $1,374,948,000. Parnassus Investments LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $731,283,000. WCM Investment Management LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $435,899,000. Loomis Sayles & Co. L P lifted its holdings in shares of Vertex Pharmaceuticals by 23.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company's stock valued at $1,519,302,000 after buying an additional 704,575 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Vertex Pharmaceuticals by 17.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock valued at $2,231,858,000 after buying an additional 704,421 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,315 shares of company stock worth $2,121,012. Insiders own 0.20% of the company's stock.

Remove Ads

Vertex Pharmaceuticals Trading Up 0.1 %

Shares of VRTX traded up $0.64 during trading hours on Tuesday, reaching $485.46. The stock had a trading volume of 335,331 shares, compared to its average volume of 1,275,697. The firm has a 50-day moving average of $477.71 and a 200 day moving average of $463.68. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The company has a market cap of $124.66 billion, a P/E ratio of -220.32, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of analyst reports. StockNews.com upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, March 11th. Bank of America lifted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research note on Monday. Cantor Fitzgerald restated an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Oppenheimer downgraded Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 19th. Finally, William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Ten research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $509.17.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.